Oruka Therapeutics names Todd Edwards as Chief Commercial Officer

Oruka Therapeutics disclosed in an 8-K that on July 22, 2026, it entered into a letter agreement with Todd Edwards under which he began serving as Chief Commercial Officer on August 24, 2026.¹

Edwards brings a background in dermatology and immunology commercialization. He most recently served as Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics from December 2024 to August 2026, overseeing commercialization of Arcutis's dermatology assets, and before that held the title of Senior Vice President and Chief Commercial Officer at Arcutis starting in September 2023¹. Earlier in his career, he was Group Vice President and Business Head of Immunology at Incyte Corporation starting in December 2020, leading commercialization of the company's dermatology unit¹. His prior roles also included stints at UCB S.A., where he headed global immunology operations and strategy from June 2019 to December 2020 and led U.S. immunology development and commercialization from June 2013 to June 2019¹, along with earlier work at AbbVie and TAP Pharmaceuticals.

On compensation, the filing states Edwards's annualized base salary is set at $525,000, with a discretionary bonus opportunity targeted at 40% of that base salary¹. He also received a stock option for 20,000 shares and RSUs covering 100,000 shares of Oruka common stock, with the option vesting 25% after one year and monthly thereafter over 36 months, and the RSUs vesting 25% at the first quarterly date after that year followed by 12 equal quarterly installments¹. Additionally, Edwards will get a $200,000 signing bonus payable within 30 days of starting, subject to partial repayment if he leaves or is terminated for cause within the first year¹.

Severance terms include 12 months of base salary and up to 12 months of company-paid health coverage if terminated without cause or if he resigns for good reason¹, with enhanced terms if termination occurs around a change in control, including 1.0 times base salary plus target bonus and full equity acceleration¹.